title: Advanced hormone-sensitive breast cancer: overcoming resistance.
abstract: Novel strategies to overcome resistance to endocrine therapy are on the horizon, especially PI3K inhibitors, CDK 4/6 inhibitors, and agents targeting methylation. However, many, if not most, patients with progressive estrogen receptor-positive breast cancer will continue to show response to multiples lines of endocrine therapy alone. Which patient subsets will be candidates for the emerging agents is still unclear, but in the future, subtype of the tumor, mutational status, and treatment goals will be part of the equation. Always, it will be necessary to individualize treatment.
authors.affiliation: Presented by Ingrid A. Mayer, MD, MSCI, Associate Professor of Medicine and Clinical Director of the Breast Cancer Program at Vanderbilt-Ingram Cancer Center, Nashville, Tennessee.
authors.forename: Ingrid A
authors.initials: IA
authors.lastname: Mayer
mesh_terms: D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000235:genetics; D019008:Drug Resistance, Neoplasm / Q000187:drug effects* / Q000235:genetics; D005260:Female; D006801:Humans; D058990:Molecular Targeted Therapy; D009154:Mutation / Q000235:genetics; D019869:Phosphatidylinositol 3-Kinases / Q000235:genetics; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D011960:Receptors, Estrogen / Q000235:genetics
chemical_list: D018931:Antineoplastic Agents, Hormonal; D047428:Protein Kinase Inhibitors; D011960:Receptors, Estrogen; D019869:Phosphatidylinositol 3-Kinases